Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer

Author： Kyula Joan N   Roulstone Victoria   Karapanagiotou Eleni M   Melcher Alan A   Harrington Kevin J  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.12, Iss.12, 2012-12, pp. : 1669-1678

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

STAT3 as a therapeutic target in head and neck cancer

By Leeman Rebecca J   Lui Vivian Wai Yan   Grandis Jennifer Rubin  

Expert Opinion on Biological Therapy, Vol. 6, Iss. 3, 2006-03 ,pp. : 231-241

Informa Healthcare

Access to resources Recommend Favorite

Head and neck cancer: Gene therapy approaches. Part 1: Adenoviral vectors

By Nemunaitis John   O'Brien John  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 2, 2002-02 ,pp. : 177-185

Informa Healthcare

Access to resources Recommend Favorite

Head and neck cancer: gene therapy approaches.Part II: genes delivered

By O’Brien John   Nemunaitis John  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 311-324

Informa Healthcare

Access to resources Recommend Favorite

Oncolytic measles viruses for cancer therapy

By Nakamura Takafumi   Russell Stephen J  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 10, 2004-10 ,pp. : 1685-1692

Informa Healthcare

Access to resources Recommend Favorite

Zalutumumab in head and neck cancer

By Schick Ulrike   Gujral Dorothy M   Richards Tom M   Harrington Kevin J   Nutting Christopher M  

Expert Opinion on Biological Therapy, Vol. 12, Iss. 1, 2012-01 ,pp. : 119-125

Informa Healthcare

Access to resources Recommend Favorite